A postdoctoral position is open in the laboratory of Dr. Richard van Rijn in the Department of Medicinal Chemistry and Molecular Pharmacology in the College of Pharmacy at Purdue University to work on a new NIH-funded R01 grant. The project proposes to study biased signal transduction pathways involved in alcohol use and anxiety-like behavior using pharmacological and pharmacogenetics tools. The experimental design will cover a wide range of skills and techniques including animal stereotaxic surgery, mouse behavior, neuronal cell culture, immunohistochemistry and Western blotting.
The successful candidate should hold a PhD or MD in pharmacology or neuroscience or related fields. Those candidates with prior experience running rodent behavior assays will be given strong preference as a major component of the work will comprise of animal studies. Additionally, experience working with G protein-coupled receptors, confocal microscopy, adeno or lentivirus, shRNA, CRISPR is considered a strength. Candidates must be fluent in spoken and written English, as evident by at least 1 first-author paper. Successful applicants are expected to work as part of a dynamic team, providing training and mentorship when appropriate to graduate and undergraduate students, but also able to work independently towards manuscripts for publication in peer-reviewed journals.
Interested candidates should submit their application letter, curriculum vitae and a minimum of 2 references that can provide letters of recommendation to firstname.lastname@example.org. Salary and benefits follow the NIH standard levels. Applications will be reviewed immediately.
Internal Number: 30032018
About Purdue University
The mission of the Van Rijn lab is to uncover new strategies to treat psychiatric and neurological disorders. We specifically investigate the heavily co-morbid triad of ?drug use disorders, chronic pain disorders and mood disorders. Our primary target, the ?delta opioid receptor, is involved in the neuropharmacology of all three disorders and thus offers an exciting novel approach to treat these disorders. The Van Rijn lab covers all aspects of preclinical drug development including drug synthesis, drug screening, pharmacological characterization both in vitro and in vivo. We also perform mechanistic studies to improve our understanding of the etiology of these disorders.